Atrial fibrillation (AF) and heart failure (HF) are prevalent cardiovascular disorders that frequently co-occur, exacerbating each other's effects and resulting in adverse clinical outcomes. Despite the well-established association between these conditions, there is a paucity of research examining AF/atrial flutter (AFL) as direct contributors to HF-related mortality across various demographics and regions within the United States. This study aims to investigate the patterns of AF/AFL-related HF mortality in the U.S. from 1999 to 2024, stratified by age, gender, race/ethnicity, urban–rural classification, and geographic region. A retrospective analysis was conducted utilizing data from the Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Mortality data were extracted from death certificates that identified AF/AFL related HF as a primary or contributing cause of death (ICD-10 codes I11.0, I13.0, I13.2, I48 and I50). Age-adjusted mortality rates (AAMRs) per 100,000 individuals were calculated, and annual percentage changes (APC) were assessed using Joinpoint regression. Between 1999 and 2024, 1,307,809 deaths in the United States were attributed to atrial fibrillation/flutter-related heart failure (AF/AFL-HF). The age-adjusted mortality rate (AAMR) rose significantly from 8.2 to 24.3 per 100,000 population. Males consistently exhibited higher AAMRs than females (15.7 vs. 12.3 per 100,000, respectively). Racial disparities were evident, with non-Hispanic Whites having the highest cumulative AAMR (15.1), and non-Hispanic Asians/Pacific Islanders the lowest (5.7). Geographic differences were also prominent: Oregon recorded the highest state-level AAMR (25.5), while Hawaii had the lowest (8.8). Regionally, the West (15.3) and Midwest (14.9) had the highest cumulative AAMRs. Place-of-death trends showed a shift toward home deaths, which became the most common location by 2024. Although AAMRs increased sharply from 2010 to 2021 across most subgroups, rates stabilized between 2021 and 2024. AF/AFL-related heart failure mortality has increased substantially over the past 26 years in the U.S. with marked disparities by sex, race/ethnicity, region, and urbanization. While recent years have seen a plateau in mortality rates, the continued burden—especially among vulnerable populations underscores the need for equitable, targeted public health interventions and improved access to cardiovascular care.

Tricuspid valve disorder (TVD), a critical aspect of valvular heart disease (VHD), significantly impacts cardiovascular health, yet its mortality trends are not well understood. This study aimed to investigate demographic and geographic disparities in TVD-related mortality across the United States from 1999 to 2023. Using data from the CDC WONDER database, death certificates were analyzed to identify TVD-related fatalities, and age-adjusted mortality rates (AAMRs) were calculated per 1,000,000 individuals. Joinpoint regression analysis was conducted to assess annual percent changes (APCs) in mortality rates. A total of 72,805 deaths were attributed to TVD. An initial steep increase in mortality rate from 1999 to 2003 (APC: 7.9%; 95% CI: 3.9 to 14.1) followed by a stable period from 2003 to 2014 (APC: 0.1%; 95% CI: -2.7 to 1.0) and a sharp increase in AAMR from 2014 to 2023 (APC: 6.5%; 95% CI: 5.2 to 8.4). Females consistently had higher mortality rates than males, with a sharper increase after 2012. Racial and ethnic disparities were evident, with American Indian and white populations experiencing higher mortality rates than black populations. Geographic disparities were also noted, with states like Oregon, Minnesota, and Vermont, as well as the West census region, showing significantly higher mortality rates. Rural areas had higher mortality rates compared to urban areas. TVD-related mortality trends have followed a complex trajectory, with marked disparities across demographic and geographic factors. Further research is required to fully understand the factors driving these trends and their public health implications.

Mesenteric cysts are rare benign intra‐abdominal tumors that are usually asymptomatic and diagnosed incidentally while being investigated for other conditions or their complications. Surgical excision remains the primary treatment option. Here we present the case of a 30‐year‐old male with progressive abdominal distension, initially misdiagnosed with liver disease and refractory ascites, leading to inappropriate diuretic therapy. Subsequent imaging revealed a giant mesenteric cyst, which was successfully managed with complete surgical excision.